{"id":"W2055183928","doi":"10.1016/j.ygyno.2011.11.042","title":"A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia","year":2011,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"Uterine Myomas and Treatments","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency; Juravinski Cancer Centre; Princess Margaret Cancer Centre","funders":"National Cancer Institute; U.S. Public Health Service","keywords":"Medicine; Aflibercept; Leiomyosarcoma; Carcinosarcoma; Sarcoma; Internal medicine; Uterine sarcoma; Surgery; Oncology; Cancer; Chemotherapy; Bevacizumab; Gynecology; Pathology; Carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002025098,0.001534238,0.001696294,0.0005095993,0.0004327218,0.0009446357,0.0007795072,0.001921115,0.005534773],"category_scores_gemma":[0.001576519,0.0006204725,0.001655686,0.0003845153,0.0008101896,0.001003218,0.0003781823,0.002928518,0.0009206785],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007212634,"about_ca_system_score_gemma":0.001646246,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001258264,"about_ca_topic_score_gemma":0.002944303,"domain_scores_codex":[0.9995942,0.0002169389,0.00001831034,0.00006568251,0.00003301385,0.00007190171],"domain_scores_gemma":[0.9991435,0.0002051666,0.0001445383,0.00005747268,0.00005344342,0.0003957915],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9016002,0.01740775,0.002616855,0.0007987322,0.001350744,0.0001536103,0.0002069826,0.001161039,0.01066596,0.0004422847,0.006538058,0.05705769],"study_design_scores_gemma":[0.9228428,0.07255616,0.002024515,0.00002789369,0.0002136821,0.00009463079,0.00002436007,0.0004322499,0.0004135639,0.0001465793,0.00121166,0.00001202145],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9781456,0.006057207,0.001141104,0.002199779,0.0007222621,0.005636646,0.002416252,0.0001564572,0.003524668],"genre_scores_gemma":[0.9645916,0.005481877,0.003231994,0.00338192,0.0007748422,0.009119843,0.004309541,0.00006300134,0.009045516],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005534773,"threshold_uncertainty_score":0.01851565,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05281627150246025,"score_gpt":0.3383873733957119,"score_spread":0.2855711018932516,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}